

I hereby certify that, on the date shown below, this correspondence is being:  
☐ deposited with the United States Postal Service in an envelope addressed to:  
COMMISSIONER FOR PATENTS, BOX NON-FEE AMENDMENT,  
WASHINGTON, D.C. 20231,  
☐ under 37CFR § 1.8(a), with sufficient postage as first class mail, or  
☐ under 37CFR § 1.10, as "Express Mail Post Office to Addressee" Mailing Label  
No. \_\_\_\_\_

**PATENT**Attorney Docket No.  
DX0935K

☒ transmitted by facsimile to the Patent and Trademark Office, Fax Number (703) 308-  
4242, Attention: Examiner Robert Hayes, Art Unit 1647

**CN 028008**Date: December 27, 2002 By: Bryce L. Current

Bryce L. Current

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Birgit OPPMANN, et al.

Serial No.: 09/521,335

Filed: March 9, 2000

For: MAMMALIAN CYTOKINES; RELATED  
REAGENTS AND METHODS

Examiner: R. Hayes

Art Unit: 1647

**RESPONSE AND AMENDMENT**

Palo Alto, California 94304

December 27, 200212/18  
199  
2/4/03

5

Commissioner for Patents  
Box: Non-Fee Amendment  
Washington, D.C. 20231

10

Sir:

This is a Response to the Communication received from the Examiner (Paper Number 11), dated November 29, 2002.

15 The Examiner states that Applicants' previous response, dated September 17, 2002, was not fully responsive to the prior restriction requirement dated July 3, 2001 (Paper Number 7). In particular, the Examiner indicates that the previous restriction requirement necessitated the choice of "... one SEQ ID NO for IL-B60 ... that forms a heterodimer with one SEQ ID NO: for CLF-1 (i.e., human vs. murine sequences)."

20 Applicants sincerely apologize to the Examiner for this oversight. For the record, Applicants understand that the requirement entails the selection of the human heterodimer (comprised of a human IL-B60 in association with a human CLF-1) or the murine heterodimer (comprised of a murine IL-B60 in association with a murine CLF-1).